Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)

This observational study will allow data to be collected to demonstrate changes in brain activity following administration of standard of care (SOC) ketamine. By comparing genetic markers across participants, data on impact of genetic markers and response to Ketamine will also be analysed.

This data will contribute to the design of future studies utilizing ketamine for various psychiatric disorders. This study will focus on treatment-resistant Major Depressive Disorder (MDD).

Topic Depression
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Entheon Biomedical
Entheon Biomedical is a listed (CSE) company that aims to develop DMT for addiction treatment.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.